CIR Share Price

Open 0.30 Change Price %
High 0.31 1 Day 0.00 0.00
Low 0.30 1 Week 0.00 0.00
Close 0.31 1 Month 0.00 0.00
Volume 70000 1 Year 0.00 0.00
52 Week High 34.70
52 Week Low 29.55
CIR Important Levels
Resistance 2 0.32
Resistance 1 0.32
Pivot 0.31
Support 1 0.30
Support 2 0.30
ASX Australia Most Active Stocks
AGO 0.02 0.00%
AGO 0.02 0.00%
AGO 0.02 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
TEG 0.05 0.00%
TEG 0.05 0.00%
TEG 0.05 0.00%
AKK 0.01 0.00%
More..
ASX Australia Top Gainers Stocks
KSO 0.40 3900.00%
IMU 0.02 100.00%
IMU 0.02 100.00%
PMQ 0.03 50.00%
ARD 0.03 50.00%
ARD 0.03 50.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
EXG 0.03 50.00%
More..
ASX Australia Top Losers Stocks
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
TCQ 0.27 -73.53%
AVD 0.01 -50.00%
AVD 0.01 -50.00%
AVD 0.01 -50.00%
SRX 16.00 -37.23%
SRX 16.00 -37.23%
More..

Circadian Technologies Ltd (ASX: CIR)

CIR Technical Analysis 4
As on 11th Dec 2015 CIR Share Price closed @ 0.31 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 0.19 & Buy for SHORT-TERM with Stoploss of 0.25 we also expect STOCK to react on Following IMPORTANT LEVELS.
CIR Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
CIR Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.circadian.com.au
CIR Address
CIR
650 Chapel Street
Suite 0403
South Yarra, VIC 3141
Australia
Phone: 61 3 9826 0399
Fax: 61 3 9824 0083
CIR Latest News
Interactive Technical Analysis Chart Circadian Technologies Ltd ( CIR ASX Australia )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Circadian Technologies Ltd
CIR Business Profile
Circadian Technologies Limited develops and commercializes therapies for cancer and eye diseases in Australia. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) C and D, and R3 targets. The company’s product pipeline includes anti-VEGFR-3 antibody that is in Phase I clinical trials for the treatment of solid tumours; VGX-100, a human antibody against VEGF-C, as a treatment for lymphedema resulting from breast cancer treatment and solid tumours; and VGX-300, a soluble form of VEGFR-3 for ‘back of the eye’ disease. It also develops diagnostic test products for cancers of unknown primaries; and blood based diagnostic tests for VEGF-C and VEGF-D as predictive and prognostic tests in lymphangioleiomyomatosis and cancer patients. The company is based in South Yarra, Australia.